StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research report released on Tuesday morning. The brokerage issued a sell rating on the stock.
Navidea Biopharmaceuticals Price Performance
Shares of NYSE:NAVB opened at $0.00 on Tuesday. Navidea Biopharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $0.15. The business has a 50-day moving average of $0.03 and a two-hundred day moving average of $0.04. The stock has a market capitalization of $100,084.00, a P/E ratio of -0.02 and a beta of 1.50.
Navidea Biopharmaceuticals Company Profile
Read More
- Five stocks we like better than Navidea Biopharmaceuticals
- Best Aerospace Stocks Investing
- Constellation Brands Stock Q1 2025: Crushing Anheuser-Busch?
- What Does a Stock Split Mean?
- Qualcomm Stock Continues to Rise in the Face of Negative News
- High Flyers: 3 Natural Gas Stocks for March 2022
- Top 3 Summer Stocks with Solid Growth Opportunities
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.